Last reviewed · How we verify

Phase III Double Blind Randomized Placebo Controlled Trial Using 20% Intra-Oral Ketoprofen Gel for Migraine Prevention.

NCT01211795 Phase 3 COMPLETED

Intra-Oral Topical Ketoprofen gel, applied to a branch of the trigeminal nerve, has been shown to prevent migraines when used once daily for 3 months in open label studies. This is a randomized, double-blind, placebo controlled phase III prevention trial to determine safety and efficacy.

Details

Lead sponsorBehar, Caren, M.D.
PhasePhase 3
StatusCOMPLETED
Enrolment67
Start date2009-10
Completion2011-06

Conditions

Interventions

Primary outcomes

Countries

United States